|drug3180||Sterile Normal Saline for Intravenous Use Wiki||1.00|
|drug710||Centricyte 1000 Wiki||1.00|
|drug2000||Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki||1.00|
|drug875||Convalescent Serum Wiki||1.00|
|drug1518||Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki||1.00|
|drug1562||IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki||1.00|
|drug1517||Hydroxychloroquine, Clindamycin Wiki||1.00|
|drug1516||Hydroxychloroquine, Azithromycin Wiki||1.00|
|drug1519||Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki||1.00|
|drug1780||Liberase Enzyme (Roche) Wiki||1.00|
|D011649||Pulmonary Alveolar Proteinosis NIH||1.00|
|D054990||Idiopathic Pulmonary Fibrosis NIH||0.71|
|D017563||Lung Diseases, Interstitial NIH||0.27|
There is one clinical trial.
Diagnostic determination of disease and treatment responses has been limited to qualitative imaging, measurement of serum markers of disease, and sampling of tissue. In each of these instances, there is a built in error either due to sensitivity and specificity issues, clinician interpretation of results, or acceptance of the use of an indirect marker (blood test) of what is happening elsewhere in the body - at the tissue level. The Fleming Method for Tissue and Vascular Differentiation and Metabolism (FMTVDM) using same state single or sequential quantification comparisons  provides the first and only patented test (#9566037) - along with the associated submitted patent applications ruled to be covered under #9566037 - that quantitatively measures changes in tissue resulting from inter alia a disease process. This includes inter alia coronary artery disease (CAD), cancer and infectious/inflammatory processes including CoVid-19 pneumonia (CVP) resulting from the metabolic and regional blood flow differences (RBFDs) caused by these diseases. The purpose of this paper is to make clinicians and researchers aware of this proposed method for investigating the prevalence and severity of CVP - in addition to providing rapid determination of treatment response in each patient, directing treatment decisions; thereby reducing the loss of time, money, resources and patient lives.
Description: Measured improvement in tissue as measured using FMTVDMMeasure: Improvement in FMTVDM Measurement with nuclear imaging. Time: 72 hours
Description: ExtubationMeasure: Ventilator status Time: 7 days
Description: Self explanatoryMeasure: Survival status Time: 30 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports